✦ LIBER ✦

Evaluation of the Practice of Antifungal Prophylaxis Use in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results From the SEIFEM 2010-B Registry

✍ Scribed by Pagano, L.; Caira, M.; Candoni, A.; Aversa, F.; Castagnola, C.; Caramatti, C.; Cattaneo, C.; Delia, M.; De Paolis, M. R.; Di Blasi, R.; Di Caprio, L.; Fanci, R.; Garzia, M.; Martino, B.; Melillo, L.; Mitra, M. E.; Nadali, G.; Nosari, A.; Picardi, M.; Potenza, L.; Salutari, P.; Trecarichi, E. M.; Tumbarello, M.; Verga, L.; Vianelli, N.; Busca, A.

Book ID: 121368783
Publisher: University of Chicago Press
Year: 2012
Tongue: English
Weight: 207 KB
Volume: 55
Category: Article
ISSN: 1058-4838
DOI: 10.1093/cid/cis773

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Azacitidine in 302 patients with WHO-def

Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group

✍ Pleyer, Lisa; Burgstaller, Sonja; Girschikofsky, Michael; Linkesch, Werner; Stau 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 955 KB

Nilotinib as frontline therapy for patie

Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd

✍ Hirohisa Nakamae; Hirohiko Shibayama; Mineo Kurokawa; Tetsuya Fukuda; Chiaki Nak 📂 Article 📅 2011 🏛 Carden Jennings Publishing 🌐 English ⚖ 289 KB

Sequential Combination of Gemtuzumab Ozo

Sequential Combination of Gemtuzumab Ozogamicin and Standard Chemotherapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase III Trial by the EORTC and GIMEMA Consortium (AML-17)

✍ Amadori, S.; Suciu, S.; Stasi, R.; Salih, H. R.; Selleslag, D.; Muus, P.; De Fab 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 249 KB

AAML03P1, a pilot study of the safety of

AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia : A report from the Children's Oncology Group

✍ Todd M. Cooper; Janet Franklin; Robert B. Gerbing; Todd A. Alonzo; Craig Hurwitz 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 385 KB 👁 2 views

The proportion of CD34+CD38low or neg my

The proportion of CD34+CD38low or neg myeloblasts, but not side population frequency, predicts initial response to induction therapy in patients with newly diagnosed acute myeloid leukemia

✍ Roshal, M; Chien, S; Othus, M; Wood, B L; Fang, M; Appelbaum, F R; Estey, E H; P 📂 Article 📅 2012 🏛 Nature Publishing Group 🌐 English ⚖ 834 KB

Adding arabinosylcytosine to idarubicin

Adding arabinosylcytosine to idarubicin induction therapy may not improve survival for people with newly diagnosed acute promyelocytic leukaemia: Abstracted from: Avvisati G, Petti M, Lo-Coco F et al. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study. LAP 0389 with 7 years of minimal follow-up. Blood 2002; 100 (9): 3141–6.

✍ Elihu Estey; Miguel A. Sanz 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 77 KB